Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Analytical Chemistry

Diagnosing Cancer By Analyzing Glycans

GC/MS technique uses 'glycan nodes' as pointers to disease-related glycosyltransferases

by Stu Borman
February 25, 2013 | A version of this story appeared in Volume 91, Issue 8

Aberrantly expressed glycosyltransferases are characteristic of a number of diseases, but detecting specific glycosyltransferases for diagnostic use is notoriously difficult. The next best thing would be to detect abnormal glycans produced by the disease-related glycosyltransferases, but single glycans cannot be directly connected to the activity of specific glycosyltransferases. A new “bottom up” (component analysis) technique devised by Chad R. Borges of the Biodesign Institute at Arizona State University and coworkers could help resolve this logjam (Anal. Chem., DOI: 10.1021/ac3035579). Noting that unusual disease-related glycans contain unique amounts of “glycan nodes”—characteristic combinations of specific sugars and linkage types—they developed a GC/MS technique to detect node levels as stand-ins for the disease-related glyco­syltransferases that produce them. They use the technique to diagnose lung cancer in blood plasma samples with 76 to 88% reliability. They believe the reliability can be improved and the technique can be extended to diagnose a variety of other conditions.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.